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Abstract
Background Remethylation defects are rare inherited disor-
ders in which impaired remethylation of homocysteine to me-
thionine leads to accumulation of homocysteine and perturba-
tion of numerous methylation reactions.
Objective To summarise clinical and biochemical characteris-
tics of these severe disorders and to provide guidelines on
diagnosis and management.
Data sources Review, evaluation and discussion of the med-
ical literature (Medline, Cochrane databases) by a panel of
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experts on these rare diseases following the GRADE
approach.
Key recommendations We strongly recommend measuring
plasma total homocysteine in any patient presenting with the
combination of neurological and/or visual and/or haematolog-
ical symptoms, subacute spinal cord degeneration, atypical
haemolytic uraemic syndrome or unexplained vascular throm-
bosis. We strongly recommend to initiate treatment with par-
enteral hydroxocobalamin without delay in any suspected
remethylation disorder; it significantly improves survival
and incidence of severe complications. We strongly recom-
mend betaine treatment in individuals with MTHFR deficien-
cy; it improves the outcome and prevents disease when given
early.
Introduction
This guideline development process was initiated within
the frame of the BEuropean network and registry for
homocystinurias and methylation defects^ (E-HOD) pro-
ject, which was started in February 2013. The main
aims of the project are the formation of a sustainable
international collaboration of experts and clinically ac-
tive centres, development of guidelines and establish-
ment of a disease registry for homocystinurias and
methylation defects. Given the often significant delays
in diagnosis and the absence of standardised treatment
protocols, the evaluation of the published knowledge
and delineation of guidelines for diagnosis and treat-
ment of these rare diseases are urgently needed. Most
of the existing studies and reports are non-systematic,
observational studies, case series or case reports, which
are generally considered to be low quality evidence.
However, following collation of the available evidence
some very consistent patterns evolved. Confirmation and
validation of our observations by insights gained from
other fields of research (e.g. vitamin B12 deficiency in
the elderly) additionally informed our interpretation of
the evidence.
Homocysteine (Hcy) is an amino acid formed from methi-
onine (Met). Under normal circumstances Hcy is converted
into cysteine (transulfuration pathway) or remethylated
(remethylation pathway) forming Met.
All genetic remethylation defects share deficient ac-
tivity of methionine synthase due to various reasons:
decreased function of the methionine synthase enzyme
protein itself or of the associated enzyme methionine
synthase reductase; deficient production of the cofactor,
methyl-cobalamin; or disturbed supply of the substrate
methyl-tetrahydrofolate (MTHF). Some genetic disorders
of intracellular cobalamin (cbl) transport and processing
(cblC, cblD-MMA/Hcy, cblF and cblJ) cause deficient
synthesis not only of methylcobalamin but also of
adenosylcobalamin, the cofactor for methylmalonyl-
CoA mutase. Those combined remethylation disorders
are associated with increased Hcy and methylmalonic
acid (MMA). 5,10-methylenetetrahydrofolate reductase
(MTHFR) deficiency leads to impaired provision of 5-
MTHF resulting in decreased function of methionine
synthase (Fowler 2005) (Fig. 1).
Our understanding of the pathophysiology of the
remethylation disorders and MTHFR deficiency is incom-
plete. At present, there are five main hypotheses: (A) direct
toxicity of metabolites, (B) missing products, (C) impaired
methylation capacity, (D) oxidative stress, (E) impaired non-
enzymatic protein functions.
(A) Hyperhomocysteinaemias are predominantly associat-
ed with neurocognitive and vascular pathology.
Homocysteine and its metabolic product, homocysteic
acid, have been implicated in provocation of seizures
in rats (Kubová et al 1995; Mares et al 1997).
Besides its impact on renal function, accumulation
of MMA along with dicarboxylic acids like 2-
methylcitrate and propionyl-CoA have been found to
induce synergistic mitochondrial dysfunction (Morath
et al 2008; Zsengellér et al 2014).
(B) Impaired methionine synthase activity with accu-
mulation of intracellular 5-MTHF (folate trap) and
subsequent disruption of nucleotide synthesis com-
promise rapidly proliferating tissues such as bone
marrow or epithelia. In MTHFR deficiency, this
trapping of folates is not found but 5-methylTHF
synthesis is impaired, resulting in low levels of
methyl-tetrahydrofolate (CH3-THF) in the central
nervous system of unknown significance (Schiff
and Blom 2012).
(C) Remethylation of homocysteine (Hcy) is an important
mechanism that maintains the methylation capacity of
the organism and removes excess Hcy. Methylation
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reactions such as DNAmethylation, creatine and myelin
synthesis utilise S-adenosylmethionine (SAM), a metab-
olite formed from Met as the methyl group donor.
Accordingly, any disorder or disruption of the Met-
Hcy-SAM pathway affects methylation capacity by
impairing multiple metabolic systems and processes
(King et al 2012; Surtees et al 1991).
(D) Enhanced oxidative stress due to a disturbance of gluta-
thione metabolism has been shown in patients with the
cblC defect and may contribute to the underlying path-
ophysiology (Pastore et al 2014).
(E) Recent data suggest that not only the accumulation of
metabolites but also the perturbed non-enzymatic func-
tions, e.g. of the MMACHC protein may add to the
pathophysiology behind the disease (Moreno-Garcia
et al 2014; Brooks et al 2016).
Methods
Panelists involved in the guideline process were invit-
ed by the EHOD project leaders according to their
expertise regarding the diseases in terms of biochem-
istry; genetics; clinical, psychosocial and laboratory
diagnosis and patient management and/or research
activities.
The PubMed and Cochrane databases were searched
using the following terms: remethylation defects OR se-
vere mthfr OR severe methylenetetrahydrofolate reduc-
tase OR cblc OR cbld OR cblf OR cblj OR cble OR
cblg OR methylmalonic aciduria homocystinuria OR
methylmalonic aciduria homocystinuria OR methylmalonic
acidemia homocysteinemia OR methylmalonic aciduria
homocysteinemia OR BCobalamin C OR Cobalamin D
OR Cobalamin E OR Cobalamin F OR Cobalamin G
OR Cobalamin J^ (last update February 2016: 834
publications).
The resulting list of publications was disposed of all
articles predominantly or only addressing other diseases
(e.g. classical homocystinuria) or MTHFR polymor-
phisms (e.g. C677T) or without information relevant to
the outcomes of interest (e.g. mutation reports only) by
screening of abstracts. In total, 174 publications were
included in the qualitative data analysis. The clinical
characterisation of the diseases (Table 1) was based on
117 publications.
The following main questions and outcomes of interest in
males and females with any type of onset (early or late) of one
of the diseases of interest were addressed (outcomes in
parentheses).
– Which clinical signs are characteristic and allow timely
diagnosis (Outcome: timely clinical diagnosis; this out-
come is considered important)
– Which biochemical parameters allow timely and valid
diagnosis? (Outcome: valid, timely laboratory diagnosis;
this outcome is considered important)
– How can we prevent death and avoid/treat severe organ
damage (Outcome: survival, severe organ complications;
this outcome is considered critical)
– How can we prevent or treat eye disease and
neurocognitive impairment? (Outcome: visual and
neurocognitive function; this outcome is considered
critical)
In a first step, all reports made available to the panelists
were graded according to the Scottish Intercollegiate
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Fig. 1 Remethylation disorders:
metabolic pathways. MTHFR
methylenetetrahydrofolate
reductase, THF tetrahydrofolate,
Gly glycine, Ser serine, DHF
dihydrohydrofolate, Met
methionine, Hcy homocysteine,
AdoMet adenosylmethionine,
AdoHcy adenosylhomocysteine,
MS methionine synthase, MSR
methionine synthase reductase,
BHMT betaine homocysteine
methyltransferase, CBS
cystathionine-beta-synthase,
DMG dimethylglycine, MeCbl
methylcobalamin, AdoCbl
adenosyl-Cbl
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Table 1 Signs and symptoms reported in 396 individuals. ++++Very frequently (>50% of cases); +++ frequently (25–50% of cases); ++ infrequently
(10–25 % of cases); + occasionally seen (<10 % of cases). (+) Single case reports, probably disease-related conditions
cblC cblD-MMA/HC cblF cblD-HC cblE cblG MTHFR deficiency
Number of reported cases 169 16 13 5 20 25 148
Eating disorders/failure to gain weight
Small for gestational age + ++ (+)
Feeding difficulties, failure to thrive +++ ++++ +++ +++ ++++ ++
Nervous system
Decreased consciousness +/− apnoea ++ (+) +++ +++ +++
Seizures +++ ++++ ++ (++) +++ +++ +++
Ataxia + (++) (+) ++ ++
Movement disorder and/or abnormal muscle tone +++ +++ +++ ++++ +++ ++++ +++
Peripheral neuropathy/subacute degeneration of spinal cord ++ (+) (++) ++ ++ ++
Hydrocephalus ++ ++ ++ ++
Visual impairment (retinopathy, optic atrophy) +++ ++ +++ ++ ++ +
Developmental disorder/ cognitive impairment +++ +++ ++++ ++++ ++++ ++++ ++++
Behavioural/mental disorders ++ ++ ++++ (+) ++
Microcephaly ++ ++++ ++ + ++
Blood and bone marrow
Megaloblastic anaemia ++ ++ +++ +++ ++++ ++++ +
Pancytopenia/neutropenia ++ +++ ++ +
Recurrent severe infections (+) ++
Kidneys
Haemolytic uraemic syndrome ++ ++ ++ (+)
Glomerulopathy + (+)
Tubulointerstitial nephropathy +
Cardiopulmonary
Cardiac malformation + +++
Cardiomyopathy ++
Interstitial pneumonia +
Pulmonary hypertension +
Vascular
Stroke (+) (+) +
Venous thrombosis/ embolism + (+) +
Malformations
Facial dysmorphism + (+)
Skeletal deformity (+) +
Gastrointestinal
Cheilitis/gastritis +++
Liver steatosis + ++
Skin
Dermatitis/rash/hyperpigmentation + ++ +
Other
Hydrops fetalis +
Metabolic acidosis and/or hyperammonaemia +
Temperature instability/hypothermia + (+)
Legend: The frequencies depicted in Table 1 are derived from collated case reports and may not be fully representative. However, they do not
significantly deviate from published case series (Ogier de Baulny et al 1998; Carrillo-Carrasco et al 2012; Fischer et al 2014; Huemer et al 2016).
The true prevalence of organ manifestations also depends on the extent of technical investigations, especially in relation to milder forms of microan-
giopathy and retinopathy that may escape clinical detection. Due to the very small number of reported cblJ cases, these have not been included
References: Fischer et al 2014; Al Essa et al 1999; Al Tawari et al 2002; Alfadhel et al 2011; Andersson et al 1999; Andersson and Shapira 1998; Arai and
Osaka 2011; Arn et al 1998; Atkinson et al 2014; Augoustides-Savvopoulou et al 1999; Backe et al 2013; Baumgartner et al 1979a; Baumgartner et al
1979b; Beauchamp et al 2009; Bellini et al 1992; Ben-Shachar et al 2012; Biancheri et al 2002; Biancheri et al 2001; Biotti et al 2014; Birnbaum et al
2008; Bishop et al 2008; Brandstetter et al 1990; Broomfield et al 2014; Brunel-Guitton et al 2010; Brunelli et al 2002; Cappuccio et al 2014; Carmel et al
1980; Carmel et al 1988; Carrillo-Carrasco et al 2009; Carrillo-Carrasco et al 2012a, b; Cerone et al 2000; Chang et al 2011; Clayton et al 1986; Coelho
et al 2008; Cogan et al 1980; D’Aco et al 2014; D’Alessandro et al 2010; De Bie et al 2009; Dionisi-Vici et al 2013; Ellaway et al 1998; Engelbrecht et al
1997; Enns et al 1999; Fuchs et al 2012; Geraghty et al 1992; Gerth et al 2008; Goodman et al 1970; Goyette et al 1996; Goyette et al 1995; Goyette et al
1994; Grant et al 2009; Grünert et al 2011; Guigonis et al 2005; Gulati et al 1997; Haan et al 1985; Harding et al 1997; Harpey et al 1981; Haworth et al
1993; Holme and Ronge 1989; Howard et al 1997; Huemer et al 2005, 2014, 2015a, b; Hyland et al 1988; Kanwar et al 1976; Kind et al 2002; Lesesve
and Latger-Cannard 2013; Levy et al 1970; Longo et al 2005; Lossos et al 2014; Mah et al 2013; Martinelli et al 2011; Matos et al 2013; Menni et al
2012;Michot et al 2008;Mitchell et al 1986;Morel et al 2005;Mudd and Freeman 1974; Nishimura et al 1985; Ogier de Baulny et al 1998; Pasquier et al
1994; Patton et al 2000; Paul et al 2013; Powers et al 2001; Prasad et al 2011; Profitlich et al 2009a, b; Regland et al 1994; Ribes et al 1990; Ricci et al
2005; Ronge and Kiellman 1996; Rosenblatt et al 1985; Rosenblatt et al 1986; Rossi et al 2001; Rutsch et al 2009; Schiff et al 2011; Schimel and Mets
2006; Selzer et al 2003; Shih et al 1989; Shinnar and Singer 1984; Sibani et al 2000; Smith and Bodamer 2002; Steen et al 1997; Stucki et al 2012;
Suormala et al 2004; Tanpaiboon et al 2013; Tomaske et al 2001; Tonetti et al 2003; Traboulsi et al 1992; Ucar et al 2010; Urbón Artero et al 2002;
Urreizti et al 2010; Visy et al 1991; Waggoner et al 1998; Wang et al 2014; Watkins and Rosenblatt 1989; Wu et al 2005
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Guidelines Network (SIGN) criteria by the authors who had
assigned themselves according to their expertise to five major
working groups focusing on the topics Bclinical signs and
symptoms^; Bdifferential diagnosis^; Blaboratory/biochemical
parameters^; Bdisease course and outcome^; Btreatment^. Due
to the rarity of the diseases, studies and reports of all types of
designs (from case reports and case series to metaanalyses)
were included; randomised controlled trials were not
available.
The working groups prepared drafts on their topics,
which were carefully evaluated in moderated discussion
groups. Elaboration and grading of recommendations was
accomplished by moderated, consensus-oriented discus-
sions according to the BGrading of Recommendations
Assessment, Development and Evaluation (GRADE) work-
ing group^ approach (http://www.gradeworkinggroup.org/;
Guyatt et al 2011a, b, c, 2012); a patient representative
was present at these meetings. Finally, for each outcome
the quality of the evidence was rated in one of three
categories (low, moderate, high) as defined by the GRADE
working group. The strength of a recommendation (strong
recommendation, recommendation and suggestion; for more
information see Supplementary material) was summarised
from written assessments from the panelist using the follow-
ing set of questions:
– Are you confident that the benefits outweigh the harms/
burden or vice versa?
– Is there high, moderate or low quality evidence? Please
consider:
Risk of bias
Study design
Directness and consistency of results
Magnitude of effect
Dose–response gradient
Publication bias
– Are you confident that the recommendation meets typical
values and preferences of the target population (e.g. pa-
tients, parents)?
– Are the resources worth the expected net benefit follow-
ing the recommendation?
– Overall strength of recommendation: weak or strong?
Data derived from case reports, case series or any
other type of observational studies were by principle
rated as low quality evidence. However, evidence for
some outcomes was considered moderate on the basis
of high consistency of results. High quality of evidence
was only available for betaine treatment in MTHFR de-
ficiency. This evidence was based on a metaanalysis,
which revealed direct and consistent results as well as
a relationship between time of onset of treatment and
outcome.
Which clinical signs are characteristic
for remethylation defects and allow for timely
diagnosis?
General clinical patterns of remethylation disorders
The published clinical presentations of patients suffering
from remethylation disorders (summarised in Table 1)
reveal no specific, distinct signs and symptoms but rath-
er highlight that these conditions affect multiple systems
and thus often present in a rather multifaceted manner.
Nevertheless, a few patterns of clinical presentations can
be identified.
Most prominently, the central and peripheral nervous
system and the bone marrow are affected. Developmental
and neurocognitive impairment, feeding problems, neuro-
logical symptoms including seizures, movement disorders,
abnormal muscle tone, visual impairment, neuropathy and
haematological abnormalities are present in the majority of
patients. In many patients, renal manifestations, e.g. atyp-
ical haemolytic uraemic syndrome (HUS) or glome-
rulopathy, mostly related to microangiopathy, have been
identified.
Clinical presentations may vary considerably. Severe
acute encephalopathy, macrocytic anaemia, atypical
HUS, cardiopulmonary signs, subacute combined degen-
eration of the cord or psychiatric symptoms, each iso-
lated or in combination with other symptoms may be
present. Therefore, in particular, a combination of neu-
rological and haematological symptoms, often in the
presence of failure to thrive or feeding difficulties
should raise suspicion of a remethylation disorder (see
references to Table 1).
Age specific patterns of remethylation disorders
Findings from published case reports indicate that the patterns
of clinical manifestation of remethylation disorders vary with
age (Table 2).
Clinical patterns specific for combined remethylation
disorders (cblC, cblD-MMA/HC, cblF, cblJ)
Severe intrauterine growth retardation is rare, whereas postna-
tal growth failure and feeding difficulties are very frequent.
Three quarters of children with combined disorders manifest
during the neonatal period or in early infancy. Neonates typ-
ically show lethargy, seizures and muscular hypotonia, often
in combination with megaloblastic anaemia or neutropenia/
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pancytopenia. Up to 50 % of infants exhibit signs of visual
impairment such as nystagmus on the background of retinop-
athy or optic atrophy (Bonafede et al 2015; Weisfeld-Adams
et al 2015; Brooks et al 2016). Microangiopathic renal or
pulmonary disease mostly manifests early but may also be
present in older children or adults (Grangé et al 2015;
Kömhoff et al 2013; Sharma et al 2007).
Older infants and young children often show signs of
acute encephalopathy; visual and cognitive impairment
are prevalent. Older children, adolescents and adults
may present with acute or chronic behavioural or psy-
chiatric abnormalities, cognitive impairment, signs of
peripheral neuropathy and ataxia that reflect subacute
degeneration of the spinal cord or rarely venous throm-
boembolism (Rahmandar et al 2014; Huemer et al 2014;
Grangé et al 2015). Other than optic pallor, ocular man-
ifestations are rare in late-onset cblC (Gizicki et al
2014; Weisfeld-Adams et al 2015).
Clinical patterns specific for isolated remethylation
disorders (cblD-HC, cblE, cblG)
The less prevalent isolated disorders of methionine syn-
thase generally present similar to combined disorders.
The typical clinical patterns of the cblE and the cblG
defect are indistinguishable. Affected individuals usually
manifest in infancy, mostly with haematological abnor-
malities, muscular hypotonia and neurocognitive impair-
ment. One third of all patients present with impaired
consciousness, seizures, and one quarter with signs of
visual impairment. Older children and adults can mani-
fest with signs reflecting spinal cord involvement (sub-
acute degeneration of the spinal cord) or psychiatric
symptoms (Huemer et al 2015a). Single cases with iso-
lated macrocytic anaemia without neurocognitive impair-
ment have been reported (Vilaseca et al 2003; Ruiz-
Mercado et al 2015).
Clinical patterns specific for MTHFR deficiency
MTHFR deficiency mainly presents in early childhood
but can potentially present at any age with a high prev-
alence of cognitive impairment. Neonates and young
infants often manifest with feeding difficulties, de-
creased consciousness, hydrocephalus and muscular hy-
potonia. Apnoea is a frequent complication (Broomfield
et al 2014; Diekman et al 2014; Huemer et al 2016;
Schiff et al 2011; Strauss et al 2007).
Older infants and children frequently manifest with sei-
zures and cognitive impairment, often displaying acquired
microcephaly. With increasing age, peripheral neuropathy,
gait abnormalities and spasticity may become evident and
some older patients manifest with additional or even isolated
behavioural or psychiatric disorders (Birnbaum et al 2008;
Michot et al 2008).
Individuals withMTHFR deficiency do not usually present
with haematological abnormalities. There are just a few
Table 2 Age-related clinical presentations of remethylation disorders
Neonates (0–28 days)
Encephalopathy
Lethargy, apnoea
Feeding difficulties
Muscular hypotonia
Seizures
Nystagmus
Anaemia/thrombocytopenia or pancytopenia, megaloblastosis
Haemolytic uremic syndrome
Cardiomyopathy
Hydrocephalus
Pulmonary hypertension
Infants (1–12 months)
Growth failure/poor weight gain
Acute progressive encephalopathy/apnoea
Chronic encephalopathy
Muscular hypotonia
Developmental disability/regression
Seizures
Recurrent acute behavioural changes/lethargy
Visual inattention/Nystagmus
Anaemia/thrombocytopenia or pancytopenia, megaloblastosis
Haemolytic uremic syndrome
Pulmonary hypertension
Children (1–12 years)
Chronic Encephalopathy
Muscular hypotonia or spasticity
Developmental disability/regression or dementia
Seizures
Neuropsychiatric disturbance/personality changes
Intermittent acute behavioural changes/lethargy
Acute progressive encephalopathy/apnoea
Subacute degeneration of the cord
Paraesthesia
Incontinence
Ataxia/spasticity
Progressive limb weakness (legs>arms)
Haemolytic uremic syndrome
Thromboembolic events
Recurrent venous thrombosis
Pulmonary thromboembolism
Cerebrovascular events
Pulmonary hypertension
Adolescents and adults (>12 years)
Chronic encephalopathy
Developmental disability/regression or dementia
Neuropsychiatric disturbance
Personality changes
Intermittent acute behavioural changes/lethargy
Acute progressive encephalopathy
Subacute degeneration of the spinal cord
Paraesthesia
Incontinence
Ataxia/spasticity
Progressive limb weakness (legs>arms)
Thromboembolic events
Recurrent venous thrombosis
Pulmonary thromboembolism
Cerebrovascular events
Pulmonary hypertension
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reports of older children and adults with megaloblastic anae-
mia in association with long-standing neurological manifesta-
tions (Broomfield et al 2014; Schiff et al 2011).
Outcome: timely clinical diagnosis
Recommendation 1: We strongly recommend consideration
of an acquired or genetic disorder of
remethylation in the case of neurologi-
cal and/or visual and/or haematological
symptoms. (Quality of the evidence:
moderate)
Recommendation 2: We strongly recommend considering
an acquired or genetic disorder of
remethylation in the case of unex-
plained thrombosis and/or spinal cord
degeneration and/or atypical HUS.
(Quality of the evidence: moderate)
Clinical differential diagnosis
All clinical presentations of genetic disorders of remethylation
can be mimicked by common conditions, which reduce
the availability of folate or cobalamin such as nutrition-
al deficiency, acquired malabsorption or drug-associated
effects (Table 3). Maternal vitamin B12 deficiency due
to a strict vegan diet or to undiagnosed pernicious
anaemia needs to be excluded in neonates and young
infants presenting with signs of a remethylation disor-
der or identified by newborn screening (NBS) and sub-
normal vitamin B12 concentrations (Scolamiero et al
2014).
A number of other rare genetic diseases can mimic
defects in intracellular cobalamin metabolism and
should be considered in children with clinical signs
and biochemical hallmarks of a remethylation disorder
but with normal serum concentrations of vitamin B12
and folates: transcobalamin (TC) deficiency is bio-
chemically and clinically indistinguishable from com-
bined cobalamin disorders (Trakadis et al 2014). The
recently discovered MTHFD1 deficiency (Watkins and
Rosenblatt 2012) affects folate metabolism and can
cause mild hyperhomocysteinaemia. The five patients
described so far displayed severe megaloblastic anae-
mia and pancytopenia, immunological problems and re-
nal microangiopathy (Burda et al 2015).
The HCFC1 X-linked defect (cbl X, Yu et al 2013) is
sometimes associated with disturbed function of the
CblC protein but its diagnosis can be challenging be-
cause not all affected boys have elevated homocysteine
concentrations. Clinical hallmarks are neonatal or early
infantile onset of severe developmental disorder, promi-
nent epileptic seizures, cognitive impairment and a dystonic-
choreatic movement disorder; moderately elevated MMA
was observed in all 14 patients reported by Yu et al 2013
(Table 4).
Which parameters allow valid and timely laboratory
diagnosis?
Patients with a suspected remethylation disorder require
immediate and urgent biochemical investigation (Fig. 2).
The diagnosis of remethylation disorders can be con-
firmed by investigations at the levels of metabolites,
enzymatic studies and/or molecular genetic analysis.
Biochemical metabolites
Plasma total homocysteine (tHcy) is the first biochemi-
cal parameter to assess when a remethylation disorder is
suspected. THcy levels usually are >50 but mostly
>100 μmol/L in untreated patients with remethylation
disorders (Carrillo-Carrasco et al 2009; Van Hove et al
2002; D’Aco et al 2014; Miousse et al 2009).
Table 3 Conditions that mimic intracellular disorders of remethylation
Affecting cobalamin availability
Nutritional inadequacy (maternal vitamin B12 deficiency/vegan diet)
Intestinal malabsorption (e.g. genetic disorders such as
Imerslund-Graesbeck syndrome gastric intrinsic factor deficiency; au-
toimmune or parasitic disease; short gut syndrome)
Disturbed binding and cellular uptake (e.g. TC deficiency)
Disturbance of intracellular metabolism (nitrous oxide)
Affecting folate availability
Nutritional inadequacy (maternal deficiency/dietary inadequacy)
Intestinal malabsorption (acquired/genetic)
Disturbed binding and cellular uptake of folate (autoimmune/genetic)
Disturbance of intracellular metabolism (antifolate drugs, MTHFD1
deficiency)
Other diseases with a combination of haematological and neurological
symptoms
Severe iron deficiency
Infectious diseases (e.g. CMV/EBV/HHV6/HPVB19/HIV1)
Leukaemia/myeloproliferative disorders
Myelodysplastic syndromes
Disorders affecting the mitochondrial respiratory chain (e.g. Pearson
syndrome)
UMP synthase deficiency (orotic aciduria)
Thiamine transporter (SLC19A2) defect
Branched chain organic acidaemia such as methylmalonic or propionic
acidaemia
Lysinuric protein intolerance
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Routinely, tHcy is measured by chromatographic methods
or immunoassays. Chromatographic methods are more specif-
ic than immunoassays and are usually coupled with tandem
mass spectrometry (MS/MS) detection allowing simultaneous
determination of other compounds of interest for diagnosis
and follow up of these diseases, e.g. Met, cysteine (Refsum
et al 2004) or possibly cystathionine (Stabler et al 1993;
Stabler et al 2013).
There is no influence of the type of collection tube
used (EDTA, heparinised, citrate, serum, gel separator
Table 4 Differential diagnosis of
inborn errors of metabolism
presenting with
hyperhomocysteinaemia
Macrocytosis or
macrocytic
anaemia
MMA Met Total vitamin
B12
Folate
cblC
cblD-MMA/HC
+ or − ↗ ↘↘ to nl nl nl
cblF/cblJ + ↗ ↘↘ to nl nl nl
cblE/G + nl ↘↘ to nl nl nl
cblD-HC + or − nl ↘↘ to nl nl nl
MTHFR – nl ↘↘ to nl nl nl or↘
Vitamin B12 deficiency or
malabsorption
+ ↗ ↘ to nl ↘↘ nl
Folate deficiency or malabsorption + nl ↘ to nl nl ↘↘
HCFC1 (cblX) + or − ↗ or nl ↘↘ to nl nl nl
CBS deficiency – nl nl-↗ nl nl
TC deficiency + ↗ ↘↘ to nl nl (↘) nl
MTHFD1 deficiency* + nl ↘↘ to nl nl nl
*Hyperhomocysteinaemia present in some patients, normal (nl) tHcy levels in others
Clinical presentation compatible with
remethylation disorder
Obtain complete diagnostic sample set: 
serum VitB12 and folate; plasma tHcy and methionine (Met);  
acylcarnitine pattern, plasma or urinary methylmalonate (MMA) 
Start parenteral hydroxocobalamin (OHCbl) (1 mg/d)
Plasma tHcy elevated; plasma Met normal or decreased
Seek expert advice!
Continue parenteral OHCbl
Consider oral betaine, folinic acid/methylfolinate, L-methionine
VitB12N, Folate N,
tHcyN, MMAN
No remethylation 
defect
VitB12 , Folate N, 
tHcy - , MMA
Perturbation of VitB12  
supply/transport 
VitB12N, Folate , 
tHcy , MMA N
Perturbation of folate 
supply/transport
VitB12N, Folate N, 
tHcy - , MMA N
cblD-HC,
cblE, cblG 
VitB12N, Folate N, 
tHcy - , MMA
CblC,cblD-MMA/HC, cblF,
cblJ or TC deficiency 
Continue parenteral OHCbl; 
Continue/start oral betaine
Continue/consider
L-methionine and/or 
folinic acid/methylfolate 
supplementation
Positive Neonatal Screening
Initiat further diagnostic steps
Supplement VitB12/folate as required 
Stop parenteral OHCbl
Continue/start oral betaine
Continue/consider 
folinic acid/methylfolate 
and/or L-methionine
supplementation
MTHFR 
deficiency
Initiate further diagnostic steps
Consider MTHFD1 deficiency
Stop parenteral OHCbl treatment
Elevated plasma total homocysteine
(tHcy)
Fig. 2 Diagnostic pathway and management of the patient with a suspected remethylation disorder. All biochemical results refer to pre-treatment
samples. N=normal
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tubes). However, blood samples should be centrifuged
within 1 h or kept cold until centrifugation (<6 h).
After removal of blood cells, tHcy is stable for several
weeks at 4 °C and for several years after freezing
(Refsum et al 2004).
Free homocystine in plasma or urine measured by conven-
tional ion-exchange chromatography is not the method of
choice since it may remain undetectable even in the presence
of significantly elevated tHcy in plasma (Fowler and Jakobs
1998; Moat et al 1999).
To further discriminate remethylation disorders from
other hyperhomocysteinaemias, determination of urinary
(or plasma) MMA (Fowler and Jakobs 1998), plasma
Met, blood acylcarnitine profile, serum vitamin B12
and folate are required and should promptly be deter-
mined (see Figs. 1 and 2). In case shipment of urine or
blood samples is difficult, an experienced laboratory
should give advice on the investigation of the parame-
ters from DBS. Treatment should not be delayed by
waiting for confirmation of the exact defect.
Outcome: valid, timely laboratory diagnosis
Recommendation 3 & Elevated plasma tHcy is the hall-
mark of remethylation disorders.
We strongly recommend that in-
vestigations in patients with a
suspected remethylation disorder
should start with the measurement
of total homocysteine in blood. We
recommend the blood sample for
tHcy to be centrifuged within an
hour and kept at +4° or frozen until
analysis. Immunoassays or chro-
matographic methods are suitable
for tHcy measurement. (Quality of
the evidence: moderate)
Recommendation 4 & We strongly recommend against
measuring free homocysteine in-
stead of total homocysteine. (Qua-
lity of the evidence: moderate)
Recommendation 5 & We strongly recommend that in the
case of high total homocysteine,
plasma and urine samples for de-
termination of MMA, methionine,
folate and vitamin B12 are to be
obtained before treatment is
started. (Quality of the evidence:
moderate)
Differential diagnosis of biochemical parameters
Hyperhomocysteinaemia is the hallmark of the remethylation
and transulfuration disorders. Mild to moderate hyperhomo-
cysteinaemia is common in vitamin B12 or folate deficiencies
but also in very severe vitamin B6 deficiency and in patients
with renal failure or hypothyroidism. While megaloblastic
anaemia with increased MCV and hypersegmented neutro-
phils on blood film are found in both vitamin B12 and folate
deficiencies, elevated MMA is only observed in functional
vitamin B12 deficiency (Whitehead 2006).
In the case of normal serum vitamin B12 and folate levels,
TC deficiency, primary remethylation and transulfuration disor-
ders should be considered. Holotranscobalamin measurement,
which unfortunately is performed only in a few laboratories
shows low levels in TC deficiency; this disorder can be con-
firmed bymolecular genetics investigation (Trakadis et al 2014).
The plasma Met concentration differentiates between
remethylation disorders and deficiency of CBS, a key enzyme
of the transulfuration pathway. Methionine is low or normal in
remethylation disorders while it is usually elevated or at least
borderline normal in CBS deficiency (Mudd 2011).
Megaloblastic anaemia with increased MCV is often ob-
served in the neonatal forms of intracellular cobalamin defects
(cblF, cblJ, cblC, cblD-MMA/HC, cblD-HC, cblE and cblG)
but less frequently in the late onset forms of these disorders
and not normally in MTHFR deficiency (Rosenblatt et al
1997; Carrillo-Carrasco et al. 2013).
The recently described HCFC1 defect (cbl X) has a different
pathophysiological background and is beyond the scope of these
guidelines. All 14 patients presented with moderately increased
MMA and five of these patients had hyperhomocysteinaemia
(Yu et al 2013). In two of the five published patients with meth-
ylenetetrahydrofolate dehydrogenase 1 deficiency, tHcy concen-
trations were moderately elevated (Burda et al 2015) (Table 4).
Enzymatic studies
Direct enzyme assays are only available for MTHFR, methio-
nine synthase and methionine synthase reductase (Suormala
et al 2002; Gulati et al 1997; Olteanu and Banerjee 2001).
These direct enzyme assays can be problematic.MTHFR should
be assayed in cultured skin fibroblasts preferably in the physio-
logical direction of the reaction (Suormala et al 2002). Apo-
methionine synthase and holo-methionine synthase (methionine
synthase plus methionine synthase reductase) activities can be
measured by the same reaction but with different conditions of
reduction (Yamada et al 2006).
Indirect assays measuring the integrity of several enzymes
in the same pathway are useful for remethylation disorders
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investigations. Incorporation of 1-[14C]-propionate into amino
acids and then cell proteins via the propionate pathway reflects
the level of intracellular synthesis of adenosylcobalamin.
Incorporation of [14C]-methyltetrahydrofolate intomethionine
explores the methionine synthase and methionine synthase
reductase activities and the capacity of the cells to produce
methylcobalamin. Incorporation of [14C]-formate into methi-
onine or serine reflects the activities of the methylene-
tetrahydrofolate dehydrogenase, methylene-tetrahydrofolate
reductase and the methionine synthase/methionine synthase
reductase activities (Table 5). These tests also allow the as-
sessment of possible in vitro vitamin-responsiveness of the
relevant disorders (Suormala et al 2002; Gulati et al 1997;
Olteanu and Banerjee 2001). Enzyme assays are needed to
characterise functional consequences of new variants identi-
fied by molecular genetic investigations including next gener-
ation sequencing.
Molecular genetic analysis
The cblC gene (MMACHCOMIM 609831) is located in chro-
mosome region 1p34.1 and has five exons (Lerner-Ellis et al
2006). The three most common mutations c.271dupA,
c.394C>T and c.331C>T have been identified in the
MMACHC gene. The c.271dupA that represents about 30 %
of the identified alleles and c.331C>T mutations are associat-
ed with early onset disease. The c.394C>T mutation is asso-
ciated mainly with late onset disease. The c.609G>Amutation
accounts for 85 % of the identified alleles in Chinese patients,
and even though it leads to a premature termination codon it
remains predominantly associated with late onset disease in
this population (Wang et al 2010) but has been observed in
some early-onset cases in other populations (Weisfeld-Adams
et al 2013). Other mutations have been shown to cluster ac-
cording to ethnicity (Morel et al 2006; Nogueira et al 2008).
The precise function of MMACHC is not completely un-
derstood. Recombinant MMACHC binds cobalamin, can
function in vitro as a cyanocobalamin (CNCbl) decyanase
(Kim et al 2008) and can dealkylate other cobalamin forms
(Hannibal et al 2009). MMACHC may act as an intracellular
cobalamin trafficking chaperone that carries out targeted de-
livery of cobalamin to and from other cobalamin-related pro-
teins (Lerner-Ellis et al 2009).
In contrast to the cblC defect which presents exclusively as
combined hyperhomocysteinaemia with MMA-uria, cblD pa-
tients can have three distinct biochemical phenotypes: isolated
hyperhomocysteinemia (cblD-HC), isolated MMA-uria
(cblD-MMA, beyond the scope of these guidelines), or com-
bined hyperhomocysteinemia and MMA-uria (cblD-MMA/
HC). MMADHC (OMIM 611935) is the gene responsible for
cblD defect (Suormala et al 2004; Coelho et al 2008).
Genotype–phenotype correlation analysis of the three cblD
variants suggests that the N- and C-terminal regions of
MMADHC have specific effects on functions in the mitochon-
drion and cytoplasm, respectively (Stucki et al 2012; Miousse
et al 2009). cblD-HC retains mitochondrial function with a
Table 5 Representation of the cobalamin defects associated with hyperhomocysteinaemia, the respective enzymatic/incorporations tests available and
the genes involved in these diseases
cblC cblD-MMA/HC cblF cblJ cblD-HC cblE cblG MTHFR
Direct enzyme assay
(tissues)
no no no no no yes yes yes
fib/leuc/amn fib/leuc/amn fib/leuc/amn
Indirect enzyme assays
Propionate incorporation ↘ ↘ ↘ ↘ nl nl nl nl
MTHF incorporation ↘ ↘ ↘ ↘ ↘ ↘ ↘ nl
Formate incorporation
into serine
↘ ↘ ↘ ↘ ↘ ↘ ↘ nl or ↗
Formate incorporation
into methionine
↘ ↘ ↘ ↘ ↘ ↘ ↘ ↘
AdoCbl biosynthesis ↘ ↘ ↘ ↘ nl nl nl nl
MeCbl biosynthesis ↘ ↘ ↘ ↘ ↘ ↘ ↘ ↘
Gene MMACHC1 MMADHC2 LMBRD13 ABCD44 MMADHC2 MTRR5 MTR6 MTHFR7
Chromosome location 1p34.1 2q23.2 6q13 14q24.3 2q23.2 5p15.31 1q43 1p36.22
Mode of inheritance AR AR AR AR AR AR AR AR
OMIM 609831 611935 612625 603214 611935 602568 156570 607093
fib fibroblasts, leuc leukocytes, amn amniocytes, AR autosomal recessive, nl normal
1 Lerner-Ellis et al 2006; 2 Coelho et al 2008; 3 Rutsch et al 2009; 4 Coelho et al 2012; 5 Leclerc et al 1998; 6 Li et al 1996; 7 Goyette et al 1994, 1995
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full-length protein which harbours only C-terminal missense
mutations in conserved residues; cblD-MMA retains cytoplas-
mic function due to translation of an error-free C-terminus
facilitated by downstream re-initiation; and in cblD-MMA/
HC complete loss of functionality occurs with deleterious mu-
tations that are localised downstream of Met116 (Jusufi et al
2014).
To date, there have been no obvious genotype-phenotype
correlations in cblF (LMBRD1, OMIM 612625) (Armour et al
2013), cblJ (ABCD4, OMIM 603214) (Coelho et al 2012),
cblE (MTRR, OMIM 602568) and cblG (MTR, OMIM
156570) (Watkins and Rosenblatt 1989; Huemer et al 2015a).
If clinical and biochemical parameters are characteristic for
a combined remethylation disorder it may be—dependent on
the population—a pragmatic approach to look first for cblC,
the most frequent remethylation disorder by searching for the
common mutation (c.271dupA) or MMACHC sequencing. If
these analyses however prove negative, functional and/or
complementation studies in fibroblasts or extended molecular
genetic testing for other defects are needed.
For MTHFR deficiency (OMIM 6070993) the majority of
mutations are private and neither type nor location of mutation
correlates with clinical phenotype (Froese et al 2016). Genetic
testing for MTFHR deficiency should be interpreted with cau-
tion since there are numerous polymorphisms in this gene,
which have been related to various common disorders and
conditions. Polymorphisms in general including the most in-
vestigated thermolabile variant c.677C>T in MTHFR are not
responsible for severe remethylation disorders (Tsang et al
2015).
Outcome: valid, timely laboratory diagnosis
Recommendation 6 & We strongly recommend diagnostic
confirmation by molecular genetic
analysis and/or direct or indirect en-
zyme assays in cultured skin fibro-
blasts (or lymphocytes) in experi-
enced laboratories. (Quality of the
evidence: moderate)
Prenatal diagnosis
Metabolites concentration (tHcy and MMA) in cell-free
amniotic fluid, enzyme activity of MTHFR and methio-
nine synthase or methionine synthase reductase in cul-
tured amniotic cells and incorporation of propionate and
methyltetrahydrofolate have been used for many years
(Fowler and Jakobs 1998; Merinero et al 1998) and
their combined use is reliable (Morel et al 2005).
Indirect enzyme assays in chorion biopsy should be
avoided (Morel et al 2005; Merinero et al 1998).
However nowadays, the molecular genetic diagnosis is the
most advisable method provided the causal mutations in the
index case and carrier status in the parents have been identi-
fied. Molecular genetic testing can be performed from chori-
onic villi or amniotic fluid samples (Morel et al 2005).
Outcome: valid, timely laboratory diagnosis
Recommendation 7 & If prenatal diagnosis is considered in
individual cases we recommend to
perform molecular genetic analysis
from chorionic villi or amniotic fluid
samples given that mutations in the
index case and carrier status in the
parents have been identified (Quality
of the evidence: low)
Feasibility and impact on outcome of newborn screening
(NBS) for combined remethylation disorders
NBS for the cblC defect should be considered since survival
and prevention of severe complications such as HUS, hydro-
cephalus and haematological abnormalities in early-onset pa-
tients can be improved by early treatment (Huemer et al
2015b). The impact of early treatment on neurocognitive de-
velopment is unclear and early treatment has little influence on
eye disease (Weisfeld-Adams et al 2013). In most late-onset
cblC patients, dementia, renal function, myelopathy and axo-
nal neuropathy improve on treatment and long-lasting disease
existing before treatment initiation correlates with residual
pathologies (Huemer et al 2014). There is insufficient data
on NBS for other combined remethylation disorders.
Outcome: survival, severe organ complications; visual and
neurocognitive function
Recommendation 8 & We strongly recommend early treat-
ment in patients with the cblC defect
as it improves survival, corrects hae-
matological abnormalities and may
prevent HUS and hydrocephalus.
However, early treatment has little
influence on eye disease and unclear
impact on neurocognitive outcome
(Quality of the evidence: moderate)
Present knowledge allows no conclusion concerning the
clinical benefit of early treatment for the cblD-MMA/HC,
cblF and cblJ defects.
The Region 4 Stork (R4S) data indicate that the sen-
sitivity of C3/C2 as primary markers is superior to Met
and Met/Phe (McHugh et al 2011). However, specificity
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of C3 and/or C3/C2 for detecting these diseases is gen-
erally low (la Marca et al 2007; Tortorelli et al 2010).
The positive predictive value substantially increased
from 4 to 100 % by measurement of MMA and 11 to
36 % by measuring tHcy as second tier analytes in DBS
(la Marca et al 2007; Tortorelli et al 2010). The sensi-
tivity of C3 and C3/C2 for mild/late-onset forms is un-
known. It is of note that neonatal metabolic distur-
bances due to maternal vitamin B12 deficiency may
also be detected. It has recently been shown that
heptadecanoyl-carnitine (C17) may have an even higher
predictive value for perturbations of MMA metabolism
including combined remethylation defects and may thus
be a promising first tier analyte (Malvagia et al 2015).
Outcome: timely and valid laboratory diagnosis
Recommendation 9 & We strongly recommend to obtain
plasma for determination of serum
vitamin B12 before treatment is
started in cases identified by NBS
as part of studies to exclude mater-
nal vitamin B12 deficiency. (Quality
of the evidence: moderate)
Recommendation 10 & We recommend use of C3 acylcar-
nitine and the C3/C2 ratio as primary
markers to screen for early onset
cblC defect. (Quality of the evi-
dence: moderate)
Recommendation 11 & We suggest consideration of C17
acylcarnitine as a promising prima-
ry marker to screen for early onset
cblC defect. (Quality of the evi-
dence: low)
Recommendation 12 & We strongly recommend performing
second tier testing using tHcy and
MMA to improve specificity and to
differentiate the defects from other
disorders. (Quality of the evidence:
moderate)
Feasibility and impact on outcome of NBS for isolated
remethylation disorders and MTHFR deficiency
The use of NBS for de tec t ion of the i so la ted
remethylation disorders and the MTHFR defect appears
worthy of consideration. In the cblE and cblG defect,
macrocytic anaemia (Vilaseca et al 2003; Kvittingen
et al 1997) and neurocognitive performance (Harding
et al 1997; Rosenblatt et al 1985; Schiff et al 2011;
Kvittingen et al 1997; Müller et al 2007) often respond
to treatment (Müller et al 2007; Schiff et al 2011). Eye
disease seems not to be responsive (Huemer et al 2014).
Early detection by NBS and timely treatment improved
short-term outcomes of two asymptomatic patients with
the cblE and cblG defect and three symptomatic patients
with MTHFR deficiency (Wong et al 2016). Moreover,
early betaine treatment has a clear positive impact on out-
come in MTHFR deficiency (Diekman et al 2014).
Neonatal screening for cblD-HC, cblE and cblG and
for MTHFR deficiency appears to be feasible by detecting
decreased methionine and methionine-to-phenylalanine
ratio (Bowron et al 2005) in DBS. The second-tier marker
tHcy clearly differentiates patients from controls
(McHugh et al 2011; Tortorelli et al 2010). However, suf-
ficient data on efficacy of NBS programs for these disor-
ders is lacking.
Outcome: survival, severe organ damage; neurocognitive
impairment
Recommendation 13 & We strongly recommend early
identification and treatment with
betaine for MTHFR deficiency.
Presymptomatic betaine treat-
ment prevents severe neurologi-
cal impairment (Quality of the
evidence: high)
Disease course and outcome of combined remethylation
disorders
Most information on complications and outcome is
based on data from patients with cblC disease. There
is limited data about the natural history of the other
combined disorders (Table 6).
Patients with the cblC defect usually present with severe
complications and historically have a poor long-term outcome
(Rosenblatt et al 1997; Andersson et al 1999; Fischer et al
2014). It is well recognised that despite treatment and im-
proved metabolic parameters, severe complications such as
developmental delay and progressive visual loss may still de-
velop (Andersson et al 1999; Enns et al 1999; Patton et al
2000; Fischer et al 2014; Weisfeld-Adams et al 2015). Even
if the neurologic status stabilises or improves with therapy, the
sequelae remain in a large proportion of patients (Whitehead
2006; Watkins and Rosenblatt 1989), especially if the initia-
tion of treatment was delayed or insufficient (Huemer et al
2014). Haematological symptoms and failure to thrive gener-
ally resolve with treatment (Martinelli et al 2011; Fischer et al
2014).
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The late-onset phenotype has a more favourable outcome
than early-onset cblC disease but is still associated with resid-
ual sequelae such as learning difficulties, neurobehavioural
symptoms, neurogenic bladder and gait abnormalities
(Rosenblatt et al 1997) and at least one patient, in whom
treatment was ceased, deteriorated and died (Thauvin-
Robinet et al 2008).
Mortality
Early detection and treatment with parenteral OHCbl appear to
have decreased the mortality in newborns with cblC. A retro-
spective analysis of 50 patients (44 presented in the first year of
life) with cblC disease reported an overall mortality rate of
30 % (Rosenblatt et al 1997). Of the 13 patients that died, four
were not treated, two received only cyanocobalamin (CNCbl),
and three were initially treated with CNCbl and then switched
to OHCbl (Rosenblatt et al 1997; Carrillo-Carrasco et al 2012).
Later, in the Fischer study about outcome in a series of 88
patients with the cblC defect, the mortality was 11.4 % (90 %
of them with infantile onset). Treatment following various
regimes of parenteral OHCbl complemented in some cases
by betaine, folate/folinic acid and carnitine resulted in im-
provement of biochemical abnormalities, non-neurological
signs and mortality (Fischer et al 2014). It has been suggested
that daily treatment with parenteral OH-Cbl combined with
betaine would be associated with a favourable outcome
(Carrillo-Carrasco et al 2012).
Renal disease and microangiopathy
Thrombotic microangiopathy (TMA) leading to atypical HUS is
the most common renal manifestation in cblC; it has also been
observed in cblD-MMA/HC patients. HUS may cause hyper-
tension, intravascular haemolysis, microscopic haematuria, pro-
teinuria and renal function deterioration, occasionally proceed-
ing to renal failure (Van Hove et al 2002; Guigonis et al 2005;
Sharma et al 2007; Geraghty et al 1992; Morath et al 2013). A
case of focal segmental glomerulosclerosis and atypical glo-
merulopathy (Brunelli et al 2002) has been reported.
Histological findings of the kidneys include widening of
the mesangium, swelling of endothelial cells with
Table 6 Main complications
according to system in
remethylation disorders
Growth and physical
features
Prenatal growth retardation and postnatal failure to thrive
Dysmorphic facial features
CNS Microcephaly
Hydrocephalus
Developmental delay and/or regression; cognitive impairment ranging from executive
dysfunction to severe mental retardation
Neuropsychiatric disturbances, social withdrawal, personality changes, dementia
Progressive encephalopathy
Seizures
Subacute combined degeneration of the spinal cord
Peripheral neuropathy
Leukoencephalopathy
Cortical atrophy
Eye Nystagmus
Maculopathy
Progressive pigmentary retinopathy
Optic atrophy
Visual impairment/blindness
Blood (Macrocytic) anaemia
Thrombocytopenia and/or neutropenia
Vascular Stroke
Recurrent venous thrombosis
Cor pulmonale or subclinical pulmonary thrombosis
Renal Haemolytic-uremic syndrome
Glomerulopathy
Heart Congenital heart defects
Left ventricular non-compaction
Dilated cardiomyopathy
Pulmonary hypertension
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detachment from the basement membrane, and granular
deposits in the subendothelial space (Van Hove et al
2002; Russo et al 1992; Brunelli et al 2002; McCully
1969). Isolated pulmonary hypertension has been ob-
served (Iodice et al 2013; Gündüz et al 2014) in cblC
patients. Early onset combined pulmonary hypertension
and renal thrombotic microangiopathy with a fatal course
in several untreated cases has been reported (Kömhoff
et al 2013), this picture is also seen in rare cases of late
onset cblC patients (Grangé et al 2015). Timely treatment
can improve outcome significantly (Grangé et al 2015;
Kömhoff et al 2013; Gündüz et al 2014).
Outcome: survival, severe organ complications
Recommendation 14 & We recommend monitoring for all
aspects of renal disease including ar-
terial blood pressure in patients with
cobalamin related remethylation dis-
orders. (Quality of the evidence:
low)
Vascular problems
Thromboembolic complications are an important cause
for morbidity and mortality in patients with cblC disease
(Martinelli et al 2011; Thauvin-Robinet et al 2008). These
include recurrent venous thrombosis (Thauvin-Robinet
et al 2008; Roze et al 2003; Augoustides-Savvopoulou
et al 1999; Bodamer et al 2001; Powers et al 2001;
Guigonis et al 2005), pulmonary thrombosis (Powers
et al 2001; Thauvin-Robinet et al 2008; McCully 1969;
Baumgartner et al 1979a, b; Van Hove et al 2002), cor
pulmonale (Profitlich et al 2009a, b) and cerebrovascular
complications (Brunelli et al 2002; Geraghty et al 1992).
tHcy levels above 45 μmol/L have been reported to be
associated with the development of vascular complica-
tions in several patients (Carrillo-Carrasco et al 2009).
Remarkably, the original case of cblC disease presenting
diffuse vascular lesions with proliferative fibrous intimal
plaques and focal necrosis of the artery wall contributed
to the development of the homocysteine theory of arterio-
sclerosis (McCully 1992).
With appropriate treatment, the incidence of thromboem-
bolic complications can be reduced and may even be
prevented in late onset patients (Huemer et al 2014).
Outcome: survival, severe organ complications
Recommendation 15 & The incidence of vascular
complications is significant-
ly reduced with appropriate
treatment in late onset pa-
tients and may be prevented
in early onset patients with
remethylation disorders.
(Quality of the evidence:
moderate)
Neurocognitive and psychiatric problems
Neurodevelopmental impairment of varying degrees is com-
mon in combined remethylation defects. Patients with early-
onset cblC disease present with a wide range of neurological
manifestations that include microcephaly, hydrocephalus, hy-
potonia, cognitive defects and seizures. Cognitive defects can
be variable, are related to disease severity and treatment onset
but may also continue to worsen despite treatment. Two treat-
ed patients with early-onset cblC disease were longitudinally
followed using neuropsychological testing. These tests
showed a decline in attention and executive functions, while
other skills were relatively spared (Beauchamp et al 2009).
Developmental delay with impairment of verbal and non-
verbal cognitive skills was also documented at follow-up of
cblF patients despite treatment (Alfadhel et al 2011; Gailus
et al 2010), but in some early treated patients, neurocognitive
outcome was satisfactory (Miousse et al 2011; Armour et al
2013). Information on outcome in the cblJ defect (Coelho et al
2012) is extremely limited; two reported patients responded
well to methylcobalamin (Kim et al 2012). In the cblD-MMA/
HC defect, some survivors showed improvement or even nor-
malisation of neurocognitive function (Suormala et al 2004;
Miousse et al 2009).
Patients with late-onset disease can show progressive en-
cephalopathy with regression, deterioration in school or work
performance, behavioural and personality changes possibly
resulting in dementia, psychosis, episodes of acute mental
confusion, lethargy and seizures that improve under specific
treatment (Huemer et al 2014).
Epilepsy is a common but nonspecific occurrence in pa-
tients with remethylation disorders. The EEG and seizure pat-
terns are nonspecific. Severely affected patients may be diffi-
cult to treat and may have recurrent status epilepticus
(Biancheri et al 2002).
Brain MRI abnormalities are common in remethylation
defects and include diffuse cerebral atrophy, white matter
changes, basal ganglia lesions and hydrocephalus.
The most common imaging findings in the early-onset
cblC cases are variable degrees of white matter abnormality
with T2 hyperintensity in periatrial and periventricular white
matter, with thinning of the corpus callosum. Basal ganglia
lesions and hydrocephalus have also been described, and may
be attributable to microvascular abnormalities (Greitz 2007).
In one cohort of young early-onset cblC patients, there was a
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high incidence of craniocaudal shortening of the pons on sag-
ittal MR images (Weisfeld-Adams et al 2013).
Cerebral atrophy and deep white matter bulk loss, which is
more pronounced posteriorly, were significant findings in late-
onset cblC disease patients (Ogier de Baulny et al 1998;
Longo et al 2005; Rossi et al 2001; Wang et al 2012).
Bilateral abnormalities of the cerebellar cortex were found in
one patient (Wang et al 2012).
The pathophysiological mechanisms underlying the white
matter abnormalities detected by MR imaging have been as-
sociated with oedema and abnormal myelination. Myelination
is closely related to methylation capacity whereby deficiency
of SAM in the CSF was shown to be associated with impaired
myelinisation (Rossi et al 2001). Moreover, a decrease in N-
acetyl aspartate (NAA) and increased lactate in the basal gan-
glia or in the periventricular white matter has been observed
on brain MR spectroscopy (Longo et al 2005; Wang et al
2012).
Spongiform white matter degeneration and demyelination
of the dorsal and lateral columns of the cord or subacute com-
bined degeneration of the spinal cord (SACD) are known com-
plications in remethylation disorders (Huemer et al 2014; Liu
et al 2015). Changes are similar to classical adult spinal cord
degeneration due to, e.g. severe nutritional vitamin B12 defi-
ciency (Scalabrino et al 2007; Maamar et al 2008). Subacute
combined degeneration of the spinal cord may be the present-
ing symptom in late onset patients or the consequence of in-
sufficient treatment. Symptoms are progressive and include
numbness of lower extremities, gait disturbances, inconti-
nence, progressive leg weakness with spastic paraparesis and
tetraplegia (Mitchell et al 1986; Ben-Omran et al 2007;
Thauvin-Robinet et al 2008; Augoustides-Savvopoulou et al
1999; Powers et al 2001; Roze et al 2003; Tsai et al 2007;
Bodamer et al 2001; Shinnar and Singer 1984).
Behavioural problems are frequent in patients with early-
onset remethylation disorders. Psychiatric manifestations
may be the presenting sign in patients with late-onset
remethylation disorders. Dementia, behavioural problems
and psychiatric symptoms have frequently been observed
in the combined (Roze et al 2003; Liu et al 2015; Huemer
et al 2014) as well in isolated remethylation disorders
(Huemer et al 2015a) and MTHFR deficiency (Birnbaum
et al 2008). In early onset cases, behavioural problems and
psychiatric symptoms can evolve over time despite treatment
(Fischer et al 2014). Late-onset cases may present with rath-
er non-specific psychiatric and behavioural symptoms,
which respond well to timely treatment (Ben-Omran et al
2007).
Ophthalmological problems
Visual dysfunction is very frequent in patients with early onset
remethylation disorders and can be rapidly progressive while
late-onset patients rarely exhibit eye disease. Current treat-
ment does not seem to modify the progression of visual dis-
ease significantly.
Maculopathy, progressive retinal dysfunction, visual im-
pairment, nystagmus, strabismus (Ricci et al 2005; Schimel
and Mets 2006; Gerth et al 2008; Weisfeld-Adams et al 2015)
and less frequently optic atrophy (Patton et al 2000; Weisfeld-
Adams et al 2015) are seen in most patients with early onset
cblC disease. Although rod cell sensitivity was reported to
improve in a patient with cblC disease following normalisa-
tion of plasma Met levels (Tsina et al 2005) generally retinal
dysfunction can be progressive and even lead to blindness
despite treatment and stabilised systemic function (Fischer
et al 2014).
The first signs of eye disease are frequently noted sev-
eral weeks after birth and include Bwandering eye
movements,^ inability to fixate and nystagmus. The fundo-
scopic exam can reveal the salt-and-pepper pigmentary
macular changes that progresses to the characteristic Bbull’s
eye^ maculopathy characterised by a hypopigmented
perimacular zone surrounded by a hyperpigmented ring or
coloboma like lesions (Robb et al 1984; Grant et al 2009;
Weisfeld-Adams et al 2015). Retinopathy can be revealed
by the electroretinogram well before clinical signs are ap-
parent (Ogier de Baulny et al 1998; Weisfeld-Adams et al
2015) showing a progressive decline in scotopic (cones)
and/or photopic (rods) responses (Schimel and Mets 2006;
Robb et al 1984; Gerth et al 2008; Gaillard et al 2008;
Weisfeld-Adams et al 2015).
Ocular coherence tomography, electroretinogram and
visual evoked potentials, are extremely useful diagnostic
and monitoring tools (Weisfeld-Adams et al 2015).
Knowledge and awareness of visual dysfunction, partic-
ularly in children with early-onset disease, allows initi-
ation of appropriate early vision intervention programs
and support (Gerth et al 2008).
Late onset patients rarely have severe visual disease (Fuchs
et al 2012; Fischer et al 2014; Gerth et al 2008). Minimal
pigmentary retinal abnormalities have been observed in some
cases (Gerth et al 2008; Weisfeld-Adams et al 2015) and the
classical Bbull’s eye^ picture has only been described in one
late-onset patient (Collison et al 2015).
Outcome: visual and neurocognitive function
Recommendation 16 & As knowledge and awareness
of visual dysfunction progres-
sion allows timely initiation of
appropriate vision interven-
tion programs and support,
we recommend that every pa-
tient newly diagnosed with a
remethylation disorder should
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receive an ophthalmological
consultation independent of
the age at diagnosis and sever-
ity of disease. (Quality of the
evidence: low)
Disease course and outcome in isolated
remethylation disorders (cblD-HC, cblE, cblG)
Disease course and outcome in isolated remethylation disor-
ders generally share many features with the combined
disorders.
Mortality
Deceased patients have been reported in the literature but the
database is too small to make a more general statement on
mortality.
Renal disease, microangiopathy and anaemia
Atypical HUS and glomerulopathy have been reported
in single patients (Paul et al 2013; Huemer et al 2015a).
Macrocytic anaemia in isolated remethylation defects
often responds to treatment (Harding et al 1997;
Vilaseca et al 2003).
Vascular problems
Thromboembolism may lead to severe clinical pathology but
has only rarely been reported (Huemer et al 2015a).
Neurocognitive and psychiatric problems
Muscular hypotonia, seizures, cognitive impairment, be-
havioural problems, psychiatric symptoms, feeding prob-
lems (Watkins and Rosenblatt 1989; Huemer et al
2015a) as well as microcephaly, brain atrophy and white
matter changes (Zavadáková et al 2005) are characteris-
tic findings during the disease course (Watkins and
Rosenblatt 1989). Hydrocephalus has rarely been report-
ed (Huemer et al 2015a).
Ophthalmological problems
Eye disease, mainly comprising retinopathy, nystagmus and
strabismus is frequently observed and seems not to respond
well to treatment (Watkins and Rosenblatt 1989; Huemer et al
2015a).
Disease course and outcome in MTHFR deficiency
Mortality
Recent experience suggests that betaine treatment if initiated
early reduces mortality in patients with MTHFR deficiency
(Diekman et al 2014)
Vascular problems
Arterial and venous thrombosis are generally rare and pre-
dominantly encountered in adolescent or adult patients (Visy
et al 1991; Tonetti et al 2002).
Neurocognitive problems
Severe neurological signs with some age-related variations
characterise MTHFR deficiency. Neurological symptoms in
MTHFR range from seizures, lethargy, apnoea and coma in
early infancy to gait disturbances with lower limb spasticity,
weakness, psychiatric behaviour such as schizophrenia-like
psychosis (Mudd and Freeman 1974; Regland et al 1994;
Pasquier et al 1994), and visual problems in adolescence/
adulthood (Haworth et al 1993; Birnbaum et al 2008).
Neonates and young infants exhibit acute neurological deteri-
oration, which may be fatal or leave severe neurological def-
icits. Older individuals typically exhibit progressive triphasic
deterioration: an initial period of normal development, then a
second phase with acquired microcephaly and psychomotor
delay, followed by abrupt deterioration associated with respi-
ratory failure that may be fatal.
In early onset severe forms clinical sequelae associated
with MTHFR deficiency include microcephaly, hydrocepha-
lus, seizures, hypotonia and global development delay, where-
as in the adolescence onset form mental retardation and pro-
gressive encephalopathy are present (Arn et al 1998; Bishop
et al 2008; Schiff et al 2011).
Some patients develop leukoencephalopathy and low-
er limb-dominant demyelinating polyneuropathy (Walk
et al 1994) and may have subacute degeneration of the
spinal cord (Hyland et al 1988). The peripheral neurop-
athy has been related to the low level of serum folic
acid (Nishimura et al 1985). Seizures are variable in
type and include myoclonic, clonic and/or tonic epi-
sodes. Infantile spasms have been described (Prasad
et al 2011). Cerebral atrophy and white matter changes
are common (Arn et al 1998; Birnbaum et al 2008).
Early treated patients exhibit a more favourable outcome
(Schiff et al 2011; Diekman et al 2014).
In MTHFR deficiency, early diagnosis and treatment are
usually associated with better neurological outcome.
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The effects of treatment on clinical outcome
Impact of prenatal treatment on outcome
Prenatal maternal treatment with parenteral OHCbl has anec-
dotally been used. For cblC disease, Trefz et al (2016) report a
favourable outcome of a pregnancy with an affected fetus
(sibling to a severely affected child) after treatment of the
mother with high-dose OHCbl (30 mg/week) and 5 mg/day
folic acid from week 15 of pregnancy. Prenatal treatment with
lower OHCbl doses resulted in biochemical improvement.
Organ complications such as microangiopathy as present in
the patient’s sibling were not observed but the patient devel-
oped eye disease and neurocognitive impairment (Huemer
et al 2005). There is no evidence regarding prenatal treatment
for the other diseases.
Outcome: survival, severe organ damage
Recommendation 17 & We suggest that prenatal mater-
nal treatment may be consid-
ered in a pregnancywith a fetus
with proven cblC disease.
(Quality of the evidence: low)
Improving the outcome in the acutely ill patient
with a suspected or proven remethylation disorder
Remethylation disorders generally present as chronic, slowly
progressive neurological disease but may also present with acute
deterioration on the background of chronic disease or with new-
onset life-threatening complications. Individuals of all ages may
manifest with a sudden thromboembolic event, microangiopath-
ic kidney or pulmonary disease, cardiomyopathy, loss of ambu-
lation or more commonly with acute encephalopathy, displaying
epileptic seizures impaired consciousness or acute behavioural
deterioration. Restoration ofmethylation capacity with appropri-
ate medication may reverse many of the acute clinical signs
(Fischer et al 2014; Huemer et al 2014) (Fig. 2).
Outcome: survival, severe organ damage; neurocognitive
impairment
Recommendation 18 & We strongly recommend im-
mediate treatment with paren-
teral cobalamin in suspected
cases. (Quality of the evi-
dence: moderate)
Recommendation 19 & We recommend consideration
of betaine treatment as soon as
hyperhomocysteinaemia is
proven and normal/low methio-
nine confirmed. (Quality of the
evidence: moderate)
Recommendation 20 & We suggest consideration of ad-
ditional enteral supplemen-
tation with folinic acid or L-
methionine in individual cases.
(Quality of the evidence: low)
Improving the outcome: long-term management
of cobalamin-related combined and isolated remethylation
disorders
Most of the knowledge about the management of remethylation
disorders is derived from the experience with individuals with
the cblC defect, the most frequent of the disorders. In clinical
practice the rarer combined disorders of the cblD-MMA/HC,
cblF and cblJ types as well as the isolated remethylation disor-
ders are generally managed identically but experience
concerning treatment efficacy is considerably less and weaker.
Treatment of individuals with the remethylation disorders
aims to improve clinical features and metabolic abnormalities
by reducing tHcy and normalising Met and—in combined
disorders—MMA (Table 7).
Cobalamin
Cobalamin is the cofactor of methionine synthase. In the
cblC defect, hydroxocobalamin (OHCbl) appears to
be more effective than cyanocobalamin (CNCbl)
(Andersson and Shapira 1998; Bodamer et al 2001).
Froese et al (2010) describe that, e.g. MMAMHC with
the c.482G>A (R161Q) mutation binds OHCbl with more
affinity than CNCbL. The parental route of administration
(IV, SQ or IM) has been proved to be beneficial in pa-
tients with the cblC defect (Van Hove et al 2002), whereas
oral OHCbl alone seems to be ineffective (Brunelli et al
2002; Bartholomew et al 1988; Gold et al 1996; Frattini
et al 2010). Long-term IV application is impracticable and
the subcutaneous route seems to be less effective than IM
injections (Thauvin-Robinet et al 2008). Many centres use
1 mg of parenteral OHCbl daily in neonates (assuming a
body weight of 3 kg, the dosage is 0.33 mg/kg/day). In
the long-term treatment, as patients stabilise, the frequen-
cy of administration is decreased to minimise the frequen-
cy of injections. However, determination of optimal doses
and intervals between injections is hampered by very
great variation in patient features (Dionisi-Vici et al
2013; Ogier de Baulny et al 1998). Some recent reports
suggest that higher OHCbl doses (plasma levels near
1,000,000 pg/ml) can provide a better metabolic control
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and dose escalation seems to be effective in several re-
ports, including a case of pregnancy in a cblC affected
female (Brunel-Guitton et al 2010). In 2002 Van Hove
et al (2002) described a good response to OHCbl dose
escalation regarding metabolic and clinical condition in
two cblC patients presenting with thrombotic microangi-
opathies (TMAs). During 13 years of follow up in a cblC
patient Carrillo-Carrasco et al (2009) observed a consid-
erable dose-dependent reduction of MMA and tHcy plas-
ma levels and an elevation of methionine levels as the
dose of IM OHCbl was increased. Matos et al 2013 per-
formed an open-label study in five cblC patients to deter-
mine the effect of OHCbl dose escalation on the clinical
and biochemical condition. They observed a goodmetabolic
response in 2/5 patients, whereas clinical response was quite
variable and not clearly related to metabolic improvement. In
early onset cblC disease, tHcy mostly cannot be normalised;
levels between 40 and 60 μmol/L are typically reached. In
some late onset patients, tHcy has been normalised.
There is limited experience with OHCbl (1000 μg/day) treat-
ment in cblD-MMA/HC disease but there seems to be a re-
sponse to treatment (Miousse et al 2009; Suormala et al 2004).
Most patients with cblE and cblG disease were treated with OH-
Cbl and seemed to benefit (Huemer et al 2015a, b). As OH-Cbl
is generally used to treat other cobalamin-related remethylation
disorders than cblC disease, no sufficient data is available on the
clinical efficacy of other cobalamin preparations .
In conclusion, OHCbl treatment is usually started at a dos-
age of 1 mg IM daily and then it should be titrated individually
based on metabolic response.
Outcome: survival and severe organ damage
Recommendation 21 & We strongly recommend using
parenteral OHCbl in treating
patients with the cblC defect and
other cobalamin-related reme-
thylation disorders. (Quality of
the evidence: high)
Recommendation 22 & We recommend applying a star-
ting dose of 1000 μg (1 mg)
OHCbl daily given parenterally
in patients with the cblC defect.
This regime has also been ap-
plied in other cobalamin-related
remethylation defects. (Quality
of the evidence: low)
Recommendation 23 & We suggest that the minimum ef-
fectiveOHCbl dose and frequency
of administration should be indi-
vidually titrated. Escalating doses
of OHCbl may result in biochem-
ical improvement; however, sig-
nificant clinical benefit remains to
be proven. Frequency of adminis-
tration of OHCbl ranges between
daily andweeklywithout evidence
of advantage of one over the other.
(Quality of the evidence: low)
Betaine
Betaine derives from choline and is a potent methyl group
donor involved in the process of remethylation of Hcy to
Met via betaine-homocysteine methyltransferase in the liv-
er, thus bypassing the MeCbl-dependent pathway. Betaine
needs to be supplemented orally and decreases Hcy levels.
The knowledge about betaine pharmacokinetics is limited
(Schwahn et al 2003). It has been suggested that frequent
administration of a moderate dose may provide clinical
and biochemical benefit (Ucar et al 2010). Betaine or
OHCbl alone may not result in sufficient metabolic
control, but they seem to have synergistic effects
(Bartholomew et al 1988). Betaine is usually administered
at a dose of up to 250 mg/kg/day in children (Beauchamp
et al 2009; Schiff et al 2011), but has been used at a dose
of 850 mg/kg/day to treat cor pulmonale in a patient with
the cblC defect (Profitlich et al 2009a, b). Betaine has also
been used during pregnancy with no neonatal adverse ef-
fect (Pierre et al 2006). Anhydrous betaine is the preferred
formulation.
Table 7 Recommended treatment of remethylation disorders
Drugs with proven clinical effect Treatments without proven clinical effect To be avoided
Cobalamin related remethylation disorders OHCbl parenteral
Betaine
Folate/folinic acid
L-Carnitine
Methionine*
Nitrous oxide
Protein restriction
MTHFR deficiency Betaine Folinic acid/ 5-Methylfolate*
L-Carnitine
Methionine*
Nitrous oxide
Folic acid
Protein restriction
*Has been applied with clinical benefit in single cases
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Outcome: survival and severe organ damage
Recommendation 24 & We recommend oral betaine
treatment in cblC disease
and other cobalamin-related
remethylat ion disorders
(Quality of the evidence: low)
Recommendation 25 & We suggest that the minimum
effective betaine dose should
be individually titrated to im-
prove the levels of tHcy and
methionine. (Quality of the
evidence: low)
Side effects of treatment with cobalamin and betaine
Few side effects related to cblC disease treatment have been
reported. These are usually scarce and reversible as soon as
the treatment is withdrawn.
OHCbl side effects such as red discoloration of the urine
and skin, hypersensitivity and photosensitivity reactions, nau-
sea, infusion site reactions and headache have rarely been
reported in patients receiving high doses. Mostly, parenteral
OHCbl even in doses as high as 20 mg per day have been
tolerated without side effects (Carrillo-Carrasco et al 2009).
In a single case, teeth discoloration occurred after 1 month
of OHCbl (1 mg/day IM) and folinic acid (10 mg/day) treat-
ment and improved after folinic acid discontinuation
(Augoustides-Savvopoulou et al 1999).
Long-tem follow up case series and case reports indicate
that betaine is generally well tolerated and safe even at high
doses (3–6 g/day in infants; 9 g/day in adults) (Ogier De
Baulny et al 1998; Thauvin-Robinet et al 2008). However,
in a 15-month-old, epileptic crises have been observed soon
after initiation of betaine treatment (250 mg/kg/day) (Enns
et al 1999).
Betaine decreases Hcy levels at the expense of increasing
Met. The clinical relevance of high Met is under discussion
but very high levels have been related to cerebral oedema. In a
10-year-old female with classical homocystinuria plasma Met
increased to >3000 μmoL/L under betaine treatment (200 mg/
kg/day). The girl developed clinical signs and radiological
evidence of cerebral oedema which resolved when betaine
was discontinued and Met levels returned to normal
(Yaghmai et al 2002). Devlin et al (2004) reported on a similar
clinical course in a boy at a plasmaMet level of 1190 μmol/L.
Therefore, caution is required and betaine should immediately
be withdrawn in any case of any symptoms suggesting in-
creased intracranial pressure or very high Met levels
(Lawson-Yuen and Levy 2006).
Folates
Folate has been frequently used as adjunctive therapy in
patients with cblC disease. Folinic acid (5-formyl-THF)
is the most stable form of the reduced vitamin and
crosses the blood brain barrier more efficiently than
folic acid (Spector 1979). Daily doses from 5 to
30 mg, divided in 2–3 administrations/week of folate
or folinic acid (Carrillo-Carrasco et al 2012; Schiff
et al 2011) have been used. In the majority of reported
patients, folic acid rather than folinic acid has been used
in the long-term treatment. In some cases no beneficial
effect of the adjunctive therapy with folic or folinic acid
has been reported (Enns et al 1999; Bartholomew et al
1988; Fischer et al 2014) but no long-term studies have
been performed.
Recommendation 26 & Results failed to demonstrate or
exclude a beneficial or detri-
mental effect of folic and/or
folinic acid as adjunctive thera-
py in patients with cblC disease
and other cobalamin-related
remethylation disorders.
(Quality of the evidence: low)
Levocarnitine
Levocarnitine facilitates the excretion of propionyl
groups and prevents carnitine deficiency, since the de
novo synthesis of carnitine depends on methionine and
may be decreased in cblC patients. Some reports in
literature show no beneficial effect of adding carnitine
to the long-term treatment of cblC disease (Enns et al
1999; Bartholomew et al 1988). There is no clear con-
sensus about the recommended dose and this can range
between 50 and 200 mg/kg/day.
Recommendation 27 & Results failed to demonstrate
or exclude a beneficial or det-
rimental effect of oral carni-
tine as adjunctive therapy in
patients with cblC disease
and other cobalamin-related
remethylation disorders.
(Quality of the evidence: low)
Dietary restrictions
Few reports describe the use of dietary restriction in cblC pa-
tients, mainly with no beneficial effect on metabolic control
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(Carrillo-Carrasco et al 2009; Enns et al 1999). Huemer et al
(2005) report significantly lower MMA excretion upon protein
restriction (methionine-free, threonine-free, valine-free,
isoleucine-low formula). However, there is evidence suggesting
a possible role of lowmethionine as a contributing factor for the
pathogenesis of cblC disease (Martinelli et al 2011) and other
remethylation disorders. Met is essential in patients with
remethylation defects and its plasma levels should be main-
tained in the normal range. Patients on protein-restricted diets
had lower height-for-age z-score. Patients consuming medical
foods with presumably lowMet supply had lower head circum-
ference and lower plasma Met concentrations (Manoli et al
2015). For these reasons, methionine-free formulas and protein
restriction leading to low methionine plasma levels is contrain-
dicated in cblC patients (Ogier de Baulny et al 1998; Manoli
et al 2015).
Outcome: survival, severe organ damage; neurocognitive
impairment
Recommendation 28 & We strongly recommend not
to restrict protein in cblC dis-
ease and other remethylation
disorders. (Quality of the evi-
dence: moderate)
Amino acid supplementation
In patients with cblC defects methionine and cysteine supple-
ments are mostly not required to maintain normal plasma
levels of these two amino acids and in a recent retrospective
multicentre study evaluating clinical, biochemical and thera-
peutic measures in 88 cblC patients (Fischer et al 2014) sup-
plemental Met was used only in one patient; cysteine supple-
mentation was never applied. Some patients were treated with
betaine and Met in combination when plasma Met was low
(Smith et al 2006).
Outcome: survival, severe organ damage; neurocognitive
impairment
Recommendation 29 & Met is essential in patients with
remethylation defects and we
recommend maintaining its
plasma levels in the normal
range; if necessary this may be
achieved by oral methionine
supplementation. (Quality of
the evidence: low)
Improving the outcome: long-term management of
MTHFR deficiency
Betaine
In MTHFR deficiency betaine in a variable dose of 100–
250 mg/kg/day in children and 5–20 g/day in adults is used
to increase systemic Met levels. A meta-analysis of case
reports (Diekman et al 2014) revealed that betaine treatment
at a dosage of 100 mg/kg/day or more was clearly associated
with increased survival. Only two of 26 patients died after
initiation of treatment. Furthermore, early treatment was as-
sociated with normal psychomotor development in all five
patients. In contrast, none of the 19 patients in the delayed-
treatment group (untreated patients excluded) had normal
psychomotor development. Nevertheless, psychomotor de-
velopment stabilised or improved in all 17 surviving patients
in whom betaine treatment was initiated late. Anhydrous
betaine is the preferred formulation.
Outcome: survival, severe organ damage; neurocognitive
impairment
Recommendation 30 & We strongly recommend early
treatment with betaine as it
improves clinical outcome
and prevents neurological de-
terioration in MTHFR defi-
ciency. (Quality of the evi-
dence: high)
See also recommendation 13
Folates
In MTHFR deficiency 5-methylTHF synthesis is impaired,
resulting in low levels of methyl-tetrahydrofolate (CH3-
THF) in the central nervous system. There have been some
reports describing the use of folic acid (5–80 mg/day) with
good (Al Tawari et al 2002; Munoz et al 2015) or poor (Holme
and Ronge 1989; Ucar et al 2010) response. A dose–response
relationship was not observed (Holme and Ronge 1989). A
combination of folic and folinic acid was associated with
favourable outcome (Tallur et al 2005; Lossos et al 2014). It
has recently been shown that folic acid may exacerbate cere-
bral CH3-THF deficiency (Hyland et al 2010) and it has there-
fore been suggested to avoid folic acid and preferably use
folinic acid or 5-CH3-THF. However, therapeutic 5-CH3-
THF in a daily dose as high as 45 mg failed to correct the
low CSF levels in a patient withMTHFR deficiency (Knowles
et al 2016; Schiff and Blom 2012). There is at present no
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consensus concerning the most effective dosage of folinic acid
or 5-CH3-THF and the problem of the assumed instability of
5-CH3-THF has not yet been solved.
Outcome: neurocognitive impairment
Recommendation 31 & Results failed to demonstrate
or exclude a beneficial or det-
rimental effect of folic or
folinic acid or 5-CH3THF as
adjunctive therapy to restore
cellular and cerebral folate de-
ficiency in MTHFR deficien-
cy on clinical outcome.
(Quality of the evidence: low).
Other substances
The data basis addressing the efficacy of vitamin B6, cobala-
min, riboflavin and carnitine is not reliable; various dosages
and combinations of these substances have been used and
their clinical efficacy cannot be assessed (Huemer et al 2016).
Methionine supplementation
In a very small number of patients, the clinical condition im-
proved with supplementation of methionine (Schiff et al 2011;
Tortorelli et al 2010), however, the data basis is not reliable
enough to allow delineation of a recommendation.
Improving clinical outcome: management of general
anaesthesia in remethylation disorders
A fatal adverse event was reported in a patient with MTHFR
deficiency anaesthetised with nitrous oxide (N2O) which is a
known inhibitor of methionine synthase (Selzer et al 2003;
Erbe and Salis 2003). In seven patients with the cblC and
one with the cblG defect, propofol was safe and effective as
an induction and maintenance agent for elective short proce-
dures in metabolically and hemodynamically stable patients
(Ktena et al 2015).
Recommendation 32 & We strongly recommend against
the use of nitrous oxide in pa-
tients with remethylation disor-
ders. (Quality of the evidence:
high)
Improving clinical outcome: management of pregnancy
in remethylation disorders
There are only three reported cases of pregnancies in
women with the cblC defect and thus no recommenda-
tions can be delineated. An asymptomatic woman was
identified when low carnitine levels were found in her
healthy child’s newborn screening sample (Lin et al
2009). Brunel-Guitton et al (2010) describe successful
outcome of a pregnancy in a treated woman with the
cblC defect. Acetylsalicylic acid at the antiplatelet oral
dose of 80 mg/day was applied during pregnancy and
delivery and specific treatment with OHCbl, folic acid
and carnitine was started at 15 weeks of gestation. The
OHCbl and carnitine administration was adjusted to
maintain a decrease of tHcy and an increase of total
carnitine plasma levels. Recently a woman with late-
onset cblC, also treated from the 15th week of gestation
and giving birth to a healthy child has been reported
(Liu et al 2015). So far, pregnancies in women with
other remethylation defects have not been reported.
Closing remarks
These guidelines are the result of the evaluation of
available information from the literature based on the
GRADE methodology and are aimed at delivering rec-
ommendations based on the best available data. The
rarity of cobalamin-related remethylation disorders and
MTHFR deficiency, the absence of larger data samples
from international registries until recently and data
mainly derived from case reports, case series or expert
opinion results in a low quality of the evidence for
several of the recommendations made. The working
group responsible for this guideline commits itself to
revise this work in the future.
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